Glymidine
-
Glymidine
structure -
-
CAS No:
339-44-6
-
Formula:
C13H15N3O4S
-
Chemical Name:
Glymidine
-
Synonyms:
Benzenesulfonamide,N-[5-(2-methoxyethoxy)-2-pyrimidinyl]-;N-[5-(2-Methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide;2-Benzenesulfonamido-5-(2-methoxyethoxy)pyrimidine;Glymidine;Glidiazine
-
CAS No:
Description
Solid
Solid
Glymidine is a sulfonamide that is N-(pyrimidin-2-yl)benzenesulfonamide which is substituted at position 5 of the pyrimidine ring by a 2-methoxyethoxy group. It is a hypoglycemic drug used for the treatment of diabetes mellitus. It has a role as a hypoglycemic agent. It is a member of pyrimidines, a sulfonamide and a diether. It is a conjugate acid of a glymidine(1-).|Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.|Glymidine is a sulfapyrimidine derivative,also known as glycodiazine, with antihyperglycemic activity. Like sulfonylureas, glymidine is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells and increasing the sensitivity of peripheral tissues to insulin.
Glymidine Basic Attributes
309.34100
309.34
222-399-2
4C5I4BQZ8F
DTXSID1023108
C72805
A - Alimentary tract and metabolism
2935009090
Characteristics
98.79000
2.45640
Solid
1.354g/cm3
153 °C
515.1ºC at 760mmHg
265.4ºC
1.588
1.24e-01 g/L
Toxicity
Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.
90% bound to plasma proteins.
Drug Information
Glycodiazine is used concomitantly with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
Rapidly and completely absorbed following oral administration.
4 hours.
The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.
glidiazine
Computed Properties
Molecular Weight:309.34
XLogP3:0.9
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:7
Exact Mass:309.07832714
Monoisotopic Mass:309.07832714
Topological Polar Surface Area:98.8
Heavy Atom Count:21
Complexity:385
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes